alnylam
The Associate Director of Scientific Communications Strategy & Excellence leads integrated engagement planning and execution across Alnylam's medical channel ecosystem for assigned therapeutic areas. This role partners with cross-functional teams to translate therapeutic priorities and audience insights into coordinated scientific communications strategies and execution-ready roadmaps. The position involves shaping medical engagement strategies, managing vendor relationships, and leveraging data to optimize scientific communications effectiveness.
Headquarters
Cambridge, Massachusetts, United States
Company Size
1001-5000 employees
Founded
2002
Alnylam is a biopharmaceutical company that has pioneered RNA interference (RNAi) therapeutics, an innovative class of medicines that treats diseases by silencing the genes that cause or contribute to them. The company develops RNAi-based medicines targeting both rare and prevalent diseases across multiple therapeutic areas, with approved products and a robust investigational pipeline. Driven by science and inspired by patients, Alnylam is committed to delivering transformational medicines that address diseases at their genetic source.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for alnylam.
Director of Medical Communications
Brinova Fastigheter AB
Director, Scientific Communications
BioCryst Pharmaceuticals
Head of Global Scientific Communications, Neurology
sanofi us
Executive Director, Medical Engagement & Scientific Communications Strategy
Amgen
Medical Director, Medical & Scientific Communications
lifelancer
Scientific Communications Contractor
Med Communications